trial · primary record
CTX-10726
Gastroesophageal Cancer (GC)
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 70 |
| Primary completion | 2028-11-01 |
| Primary endpoint | Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses |
| Registry ID | NCT07419841 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:32.103Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07419841
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.